T1	Participants 88 133	newly diagnosed stage 1 hypertensive patients
T2	Participants 659 757	The study included 60 newly diagnosed stage 1 hypertensive patients with no other systemic disease
T3	Participants 791 952	receive nebivolol 5 mg (30 patients; 21 women, 9 men; mean age 48.4 ± 11.4 years) and valsartan 160 mg (30 patients; 21 women, 9 men; mean age 49.8 ± 11.3 years)
#1	AnnotatorNotes T3	2 different groups involved in the trial
